Literature DB >> 16120192

Improvement of insulin resistance by Acanthopanax senticosus root in fructose-rich chow-fed rats.

Tsang-Pai Liu1, Chyou-Shen Lee, Shorong-Shii Liou, I-Min Liu, Juei-Tang Cheng.   

Abstract

1. In an attempt to develop new substances for handling insulin resistance, an aqueous extract of the root of Acanthopanax senticosus (Araliaceae) was used to screen the effect on insulin resistance induced by fructose-rich chow in rats. 2. Insulin action on glucose disposal rate was measured using the glucose-insulin index, the product from areas under the curve of glucose and insulin during the intraperitoneal glucose tolerance test. In addition to the modification of feeding behaviour and a marked decrease in bodyweight, oral administration (three times daily for 3 days) of the aqueous extract of A. senticosus root to rats that had received fructose-rich chow for 4 weeks reversed the elevated value of the glucose--insulin index, indicating that this herb has the ability to improve insulin sensitivity. 3. Time for the loss of the plasma glucose-lowering response to tolbutamide (10.0 mg/kg, i.p.) in fructose-rich chow-fed rats was markedly delayed by repeated treatment with the aqueous extract of A. senticosus root compared with the vehicle (saline) -treated group. Thus, an improving effect of A. senticosus root on insulin resistance can be considered. 4. An increase in insulin sensitivity following the administration of this herb was further identified using the plasma glucose-lowering action of exogenous insulin in streptozotocin (STZ)-diabetic rats. Oral administration of the aqueous extract of A. senticosus root at a dose of 150.0 mg/kg three times daily to STZ-diabetic rats increased the responses to exogenous insulin 10 days later. 5. The results obtained suggest that oral administration of the aqueous extract from A. senticosus root has the ability to improve insulin sensitivity and delay the development of insulin resistance in rats and, thus, may be used as an adjuvant therapy for patients with insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120192     DOI: 10.1111/j.0305-1870.2005.04245.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

1.  Antidiabetic Activities of Abutilon indicum (L.) Sweet Are Mediated by Enhancement of Adipocyte Differentiation and Activation of the GLUT1 Promoter.

Authors:  Chutwadee Krisanapun; Seong-Ho Lee; Penchom Peungvicha; Rungravi Temsiririrkkul; Seung Joon Baek
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-17       Impact factor: 2.629

Review 2.  Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects.

Authors:  Ravirajsinh Jadeja; Ranjitsinh V Devkar; Srinivas Nammi
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-03       Impact factor: 2.629

3.  Bioactivity-Guided Identification of Botanical Inhibitors of Ketohexokinase.

Authors:  MyPhuong T Le; Miguel A Lanaspa; Christina M Cicerchi; Jatinder Rana; Jeffrey D Scholten; Brandi L Hunter; Christopher J Rivard; R Keith Randolph; Richard J Johnson
Journal:  PLoS One       Date:  2016-06-20       Impact factor: 3.240

4.  Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats.

Authors:  Ning Zhang; Xu-Hui Wang; Shi-Long Mao; Feng Zhao
Journal:  Molecules       Date:  2011-05-10       Impact factor: 4.411

5.  Astragaloside IV promotes the eNOS/NO/cGMP pathway and improves left ventricular diastolic function in rats with metabolic syndrome.

Authors:  Xin Lin; Qiongying Wang; Shougang Sun; Guangli Xu; Qiang Wu; Miaomiao Qi; Feng Bai; Jing Yu
Journal:  J Int Med Res       Date:  2019-03-07       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.